跳轉至內容
Merck
全部照片(1)

重要文件

SCP0076

Sigma-Aldrich

Caspase 2 Inhibitor (ICH-1)

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C23H37N5O10
分子量::
543.57
分類程式碼代碼:
12352200
NACRES:
NA.32

化驗

≥95% (HPLC)

形狀

lyophilized

成份

Peptide Content, ≥80%

儲存條件

protect from light

儲存溫度

−20°C

Amino Acid Sequence

Ac-Val-Asp-Val-Ala-Asp-al

應用

Caspase 2 Inhibitor (Ac-VDVAD-CHO) is a non-selective (also inhibits caspase 3) but powerful inhibitor of caspase 2 used to study the role of caspase 2 in cell processes.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 1

1 of 1

Michel C Maillard et al.
Bioorganic & medicinal chemistry, 19(19), 5833-5851 (2011-09-10)
Several caspases have been implicated in the pathogenesis of Huntington's disease (HD); however, existing caspase inhibitors lack the selectivity required to investigate the specific involvement of individual caspases in the neuronal cell death associated with HD. In order to explore
Bin Fang et al.
Journal of molecular biology, 360(3), 654-666 (2006-06-20)
The molecular basis for the substrate specificity of human caspase-3 has been investigated using peptide analog inhibitors and substrates that vary at the P2, P3, and P5 positions. Crystal structures were determined of caspase-3 complexes with the substrate analogs at
Ju Youn Kim et al.
Cell, 175(1), 133-145 (2018-09-18)
Nonalcoholic fatty liver disease (NAFLD) progresses to nonalcoholic steatohepatitis (NASH) in response to elevated endoplasmic reticulum (ER) stress. Whereas the onset of simple steatosis requires elevated de novo lipogenesis, progression to NASH is triggered by accumulation of hepatocyte-free cholesterol. We

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務